Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  10-K
Filing Date:  2/16/2011 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 600
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.29  
Change: 
-0.08 (-3.38%)  
Trade Time: 
Oct 22  
Market Cap: 
$343.85M
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. We are primarily focused on commercializing PIXUVRI�(pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe.
Register for a Free Trial and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business
      Item 1a. Risk Factors
      Item 1b. Unresolved Staff Comments
      Item 2. Properties
      Item 3. Legal Proceedings
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Consolidated Financial Data
      Item 7. Management's Discussion and Analysis of Consolidated ...
        Results of Operations
        Liquidity and Capital Resources
      Item 7a. Quantitative and Qualitative Disclosures about ...
      Item 8. Consolidated Financial Statements and Supplementary Data
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON ...
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers and Corporate Governance
        NAME AND TITLE
        NAME AND TITLE
      Item 11. Executive Compensation
        BENEFICIAL OWNERS
        COMPENSATION TABLE
      Item 12. Security Ownership of Certain Beneficial Owners and ...
        BENEFICIAL OWNERS
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accounting Fees and Services
    PART IV
      Item 15. Exhibits, Financial Statement Schedules
    Report of Stonefield Josephson, Inc, Independent Registered ...
    Reports of Marcum LLP, Independent Registered Public ...
    SIGNATURES
  EXHIBIT 10.24
  EXHIBIT 12.1
  EXHIBIT 21.1
  EXHIBIT 23.1
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT
  EXHIBIT 23.2
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER
  EXHIBIT 32
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL ...